Bipolar Disorder
Conditions
Brief summary
The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.
Detailed description
Pediatric Bipolar Disorder (PBD) severely impairs a child's emotional development, and is associated with alarming rates of suicide, school failure, aggression, risk taking behaviors and substance abuse (Geller et al, 1998; 2001; Carlson et al, 1998). At present, very little is known about the pathophysiology or optimal treatment of PBD. The long range goals of this proposal are threefold: to investigate a range of pharmacotherapeutic agents that are safe and efficacious for PBD, to use fMRI techniques to examine abnormalities in brain function in this disorder, as well as any change in brain function after treatment. In contrast to the adult literature, we are aware of only two prospective studies assessing the efficacy of standard mood stabilizers in a pediatric sample. In one, lithium was found to be moderately effective in PBD with comorbid substance abuse (Geller et al, 1998). In the other, divalproex sodium, lithium and carbamazepine produced a maximum of 50% symptom reduction (Kowatch et al, 2000). Subsequently, Kafantaris et al (2001) observed a potentiation of lithium's antimanic effect when combined with risperidone. Further, a prospective, open trial of olanzapine for PBD reported a 70% symptom reduction (Frazier et al, 2001) with a retention rate of 96% compared to only 7% with classic mood stabilizers (Kowatch et al, 2000). Thus, parallelling adult studies (Sachs et al, 2000), novel antipsychotics are a promising treatment in this population. Further, up to 60% of acute PBD episodes present with psychotic features (Geller et al, in press). Finally, the time to full effect with mood stabilizers is often 4 weeks in children (Kowatch et al, 2000; Geller et al, 1998; Kafantaris et al, 2001), whereas antipsychotics usually have a more rapid response onset (Pavuluri et al, in press). Given the potential efficacy of novel antipsychotics for PBD, the aim is to conduct a randomized trial comparing a novel antipsychotic to a standard mood stabilizer:
Interventions
Divalproex sodium is a mood stabilizer
Risperidone is a second generation antipsychotic and antimanic drug
Sponsors
Study design
Eligibility
Inclusion criteria
* Children with Bipolar Disorder * Must be able to swallow tablets
Exclusion criteria
* Children with general medical condition such as head injury, epilepsy, endocrine disorders * Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings. * If we discover during the interview that the parent and/or child does not understand the consent/assent procedures, we will exclude them. We expect only a small number of children to be excluded from the study due to exclusionary criteria. Selection of the subjects is not based on sex, race, or ethnic group.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Young Mania Rating Scale (YMRS) | Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point). | This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. We show the mean and standard deviation at week 0 and 6. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Child Depression Rating Scale- Revised (CDRS-R) | Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point). | Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation are measured in this study to illustrate outcome at baseline and when the subject ended the study. |
| Child Mania Rating Scale (CMRS) | Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point). | Child Mania rating scale is a parent rated measure to screen for symptoms of mania. It includes 21 items reflecting the DSM-IV criteria for a manic episode. Each item is answered on a four-point Likert type scale anchored by 0 (Never/Rare), 1 (Sometimes), 2 (Often), and 3 (Very Often). Maximum score possible is 63. Score higher than 20 is considered clinically significant, and this is a dimensional score of manic severity. |
| Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall) | Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point). | Severity of Illness and Global Improvement are rated on a 7-point scale by the clinician. In addition to rating the overall illness with the CGI-BP, severity and improvement are considered on various other dimensions such as mania, depression, attention deficit/hyperactivity, psychosis, aggression and sleep difficulties. Score of 1, 2 and 3 would mean there is clinically observed symptom improvement where 1 is the best outcome than 2 or 3. The point 4 is the point where the subject presents at baseline of that specific individual. If they become worse on clinical symptoms, they are rated as 5, 6 or 7 where 7 is worse than 5. |
Countries
United States
Participant flow
Recruitment details
Dates of recruitment :From Sep2005 - Jan 2008.in Clinic Subjects enrolled:65
Pre-assignment details
Exclusion Criteria: * Children with general medical condition such as head injury, epilepsy, endocrine disorders * Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings.
Participants by arm
| Arm | Count |
|---|---|
| Risperidone Risperidone is an antipsychotic medication and is used to treat mania. Its trade name is Risperdal.
Aim of the study is to cross compare the relative efficacy and safety of risperidone and divalproex sodium in treating/stabilizing mania in pediatric bipolar disorder. | 32 |
| Divalproex Divalproex sodium, also referred to as divalproex is an antiepileptic medication used for mania and is referred to as mood stabilizer. Its trade name is Depakote. | 33 |
| Total | 65 |
Baseline characteristics
| Characteristic | Risperidone | Divalproex | Total |
|---|---|---|---|
| Age, Continuous | 10.47 years STANDARD_DEVIATION 3.18 | 11.23 years STANDARD_DEVIATION 3.5 | 10.85 years STANDARD_DEVIATION 3.34 |
| Region of Enrollment United States | 32 participants | 33 participants | 65 participants |
| Sex: Female, Male Female | 12 Participants | 14 Participants | 26 Participants |
| Sex: Female, Male Male | 20 Participants | 19 Participants | 39 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / 32 | 10 / 33 |
| serious Total, serious adverse events | 0 / 32 | 0 / 33 |
Outcome results
Young Mania Rating Scale (YMRS)
This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. We show the mean and standard deviation at week 0 and 6.
Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
Population: Inclusion criteria were a DSM-IV diagnosis of bipolar disorder Type I (mixed or manic episode); 8 to 18 years old; and medication free or currently clinically unstable on medication, justifying termination of the ineffective regimen.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Divalproex | Young Mania Rating Scale (YMRS) | Baseline | 25.09 units on a scale | Standard Deviation 7.51 |
| Divalproex | Young Mania Rating Scale (YMRS) | Last observation carried forward (LOCF) | 15.24 units on a scale | Standard Deviation 12.49 |
| Risperidone | Young Mania Rating Scale (YMRS) | Baseline | 30.59 units on a scale | Standard Deviation 7.04 |
| Risperidone | Young Mania Rating Scale (YMRS) | Last observation carried forward (LOCF) | 10.22 units on a scale | Standard Deviation 10.5 |
Child Depression Rating Scale- Revised (CDRS-R)
Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation are measured in this study to illustrate outcome at baseline and when the subject ended the study.
Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Divalproex | Child Depression Rating Scale- Revised (CDRS-R) | Baseline | 40.76 units on a scale | Standard Deviation 13.34 |
| Divalproex | Child Depression Rating Scale- Revised (CDRS-R) | Last Observation Carried Forward (p<.01) | 35.76 units on a scale | Standard Deviation 15.01 |
| Risperidone | Child Depression Rating Scale- Revised (CDRS-R) | Baseline | 41.72 units on a scale | Standard Deviation 17.44 |
| Risperidone | Child Depression Rating Scale- Revised (CDRS-R) | Last Observation Carried Forward (p<.01) | 25.88 units on a scale | Standard Deviation 9.13 |
Child Mania Rating Scale (CMRS)
Child Mania rating scale is a parent rated measure to screen for symptoms of mania. It includes 21 items reflecting the DSM-IV criteria for a manic episode. Each item is answered on a four-point Likert type scale anchored by 0 (Never/Rare), 1 (Sometimes), 2 (Often), and 3 (Very Often). Maximum score possible is 63. Score higher than 20 is considered clinically significant, and this is a dimensional score of manic severity.
Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Divalproex | Child Mania Rating Scale (CMRS) | Baseline | 30.84 units on scale | Standard Deviation 10.87 |
| Divalproex | Child Mania Rating Scale (CMRS) | LOCF | 16.35 units on scale | Standard Deviation 13.09 |
| Risperidone | Child Mania Rating Scale (CMRS) | LOCF | 19.20 units on scale | Standard Deviation 12.66 |
| Risperidone | Child Mania Rating Scale (CMRS) | Baseline | 28.0 units on scale | Standard Deviation 9.02 |
Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall)
Severity of Illness and Global Improvement are rated on a 7-point scale by the clinician. In addition to rating the overall illness with the CGI-BP, severity and improvement are considered on various other dimensions such as mania, depression, attention deficit/hyperactivity, psychosis, aggression and sleep difficulties. Score of 1, 2 and 3 would mean there is clinically observed symptom improvement where 1 is the best outcome than 2 or 3. The point 4 is the point where the subject presents at baseline of that specific individual. If they become worse on clinical symptoms, they are rated as 5, 6 or 7 where 7 is worse than 5.
Time frame: Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Divalproex | Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall) | Baseline | 4.80 units on a scale | Standard Deviation 1.06 |
| Divalproex | Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall) | LOCF | 2.77 units on a scale | Standard Deviation 1.28 |
| Risperidone | Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall) | Baseline | 4.37 units on a scale | Standard Deviation 0.67 |
| Risperidone | Clinical Global Improvement in Bipolar Disorder Overall (CGI-BP Overall) | LOCF | 2.97 units on a scale | Standard Deviation 1.5 |